Alyeska Investment Group
CLDX icon

Alyeska Investment Group’s Celldex Therapeutics CLDX Stock Holding History

Alyeska Investment Group’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-9,715
Closed -$1.89M – 492
2014
Q3 		$1.89M Buy
9,715
+1,286
+15% +$280K 0.04% 296
2014
Q2 		$2.06M Buy
8,429
+5,096
+153% +$1.15M 0.05% 310
2014
Q1 		$884K Sell
3,333
-3,614
-52% -$1.38M 0.02% 301
2013
Q4 		$2.52M Buy
+6,947
New +$2.68M 0.1% 220

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Alyeska Investment Group's CLDX Position: Q4 2014 in Review

Alyeska Investment Group sold out of Celldex Therapeutics (CLDX) in Q4 2014, closing a stake of 9,715 shares — an estimated $1.89M sold.

Alyeska Investment Group first reported a position in CLDX in Q4 2013 and held it in 4 quarters. The position peaked at $2.52M in Q4 2013. 163 funds tracked by Wall St. Rank hold CLDX as of Q4 2014.

  • Alyeska Investment Group reported no remaining Celldex Therapeutics position as of Q4 2014 after selling out during the quarter.
  • Alyeska Investment Group sold 9,715 Celldex Therapeutics shares in Q4 2014, an estimated $1.89M.
  • Alyeska Investment Group first reported a position in Celldex Therapeutics in Q4 2013 and held it in 4 quarters.
  • Alyeska Investment Group's Celldex Therapeutics position peaked at $2.52M in Q4 2013.
  • 163 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2014.

Based on Alyeska Investment Group's 13F filing for Q4 2014, filed 17 Feb 2015.